NCOR1
NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Prostate cancer, Lung cancer and 5 more.
Overview
Mediates transcriptional repression by certain nuclear receptors. Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors. Participates in the transcriptional repressor activity produced by BCL6.
Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.23, somatic mutation 0.96). IntOGen calls it a driver in 18 cohorts (3 activating, 15 loss-of-function), covering Acute Lymphoblastic Leukaemia, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cholangiocarcinoma, Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Prostate cancer, Lung cancer and 5 more.
- 1 · What it is
NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Prostate cancer, Lung cancer and 5 more.
- 2 · What goes wrong in cancer
Mediates transcriptional repression by certain nuclear receptors. Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors.
- 3 · How drugs use it
No product in this corpus aims at NCOR1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7672 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75376 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000141027 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.55, melanoma 0.52, skin cancer 0.55, breast cancer 0.70, lung cancer 0.59, biliary tract cancer 0.51 (GraphQL API, CC0)); IntOGen NCOR1 (driver in 18 cohorts (Act 3, LoF 15); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Mediates transcriptional repression by certain nuclear receptors. Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors. Participates in the transcriptional repressor activity produced by BCL6. Recruited by ZBTB7A to the androgen response elements/ARE on target genes, negatively regulates androgen receptor signalling and androgen-induced cell proliferation. Mediates the NR1D1-dependent repression and circadian regulation of TSHB expression. The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver. Location: Nucleus (UniProt). Locus 17p12-p11.2 (HGNC).
- Breast cancer: Open Targets association 0.70 with breast cancer (MONDO_0007254); IntOGen driver in 6 cohorts (BRCA)
- Prostate cancer: IntOGen driver in 2 cohorts (PRAD, PROSTATE)
- Lung cancer: Open Targets association 0.59 with lung cancer (MONDO_0008903)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Mesothelioma: IntOGen driver in 1 cohort (PLMESO)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 15 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NCOR1" OR ABSTRACT:"NCOR1" OR TITLE:"nuclear receptor corepressor 1" OR ABSTRACT:"nuclear receptor corepressor 1" OR TITLE:"Nuclear receptor corepressor 1" OR ABSTRACT:"Nuclear receptor corepressor 1" OR TITLE:"N-CoR" OR ABSTRACT:"N-CoR" OR TITLE:"hCIT529I10" OR ABSTRACT:"hCIT529I10" OR TITLE:"TRAC1" OR ABSTRACT:"TRAC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NCOR1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGRIN2A
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetNOTCH2
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetTP63
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).